Drug Profile
Pixatimod - Zucero Therapeutics
Alternative Names: PG-545; PG500 programLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Progen Pharmaceuticals
- Developer Bristol-Myers Squibb; Mayo Clinic; Medigen Biotechnology Corporation; Progen Pharmaceuticals Limited; Zucero Therapeutics
- Class Antineoplastics; Cholestanols; Glycosaminoglycans; Oligosaccharides; Small molecules; Sulfates
- Mechanism of Action Dendritic cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer; Malignant melanoma; Non-small cell lung cancer
- Preclinical Ovarian cancer
- No development reported Liver cancer; Pancreatic cancer; Solid tumours
- Discontinued Breast cancer
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 18 Nov 2021 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05061017)